J4

• 基础研究 • 上一篇    下一篇

胰激肽原酶对自发性高血压大鼠心肌纤维化及NO含量的影响

付 军, 冷吉燕,杜 萍,李颖新,刘补尚   

  1. 吉林大学第一医院干部病房,吉林 长春130021
  • 收稿日期:2006-03-09 修回日期:1900-01-01 出版日期:2006-09-28 发布日期:2006-09-28

Effects of pancreatic kininogenase on myocardical fibrosis and serum nitric oxide level in spontaneously hypertensive rats

FU Jun,LENG Ji-yan,DU Ping,LI Ying-xin,LIU Bu-shang   

  1. Department of Cadre Ward,First Hospital,Jinlin University, Changchun 130021, China
  • Received:2006-03-09 Revised:1900-01-01 Online:2006-09-28 Published:2006-09-28

摘要: 目的:探讨胰激肽原酶对自发性高血压大鼠(SHR)血压、心肌纤维化及血清一氧化氮(NO)含量的影响。方法:雄性15周龄SHR 24只,随机分成SHR组、胰激肽原酶组和卡托普利组,每组8只,另取8只雄性15周龄Wistar大鼠作为正常血压对照组。胰激肽原酶组腹腔注射(7.2 U•kg-1•d-1),卡托普利组灌胃给药(10 mg•kg-1•d-1),SHR组和正常血压对照组给0.9% NaCl溶液腹腔注射(2 mL•kg-1•d-1),各组均连续4周给药。实验4周后行颈动脉插管测量血压,然后处死动物,测量各组左心室重量指数(LVMI)、心肌胶原体积比例(CVF)、心肌血管周围胶原与管腔面积的比例(PVCA)及血清NO含量。结果:SHR组SBP、LVMI、CVF、PVCA增高,血清NO含量下降,与正常血压对照组比较差异均具有显著性(P<0.05)。用药4周后,胰激肽原酶组SBP、LVMI、CVF及PVCA均较SHR组显著下降,两组比较差异均具有显著性(P<0.05);胰激肽原酶组NO含量明显升高且接近正常血压对照组水平;胰激肽原酶组除SBP外的各项指标与卡托普利组比较差异均无显著性(P>0.05)。结论:胰激肽原酶具有降低SHR血压和逆转心肌纤维化的作用,其机制可能与增加NO含量有关。

关键词: 治疗应用, 一氧化氮, 心内膜心肌纤维化, 大鼠, 近交SHR

Abstract: Objective To investigate the effects of pancreatic kininogenase on pressure,myocardical fibrosis and serum nitric oxide (NO) level in spontaneously hypertensive rats (SHR). Methods Twenty-four (fifteen weeks) male SHR were randomly divided into three groups:SHR group,pancreatic kininogenase group and captopril group(n=8 ),8 male Wistar kyoto rats with normal blood pressure were considered as control group. Pancreatic kininogenase was given by peritoneal injection (7.2 U•kg-1•d-1), captopril was given by intragast ric administration(10 mg•kg-1•d-1), the rats in SHR group and rats with normol blood pressure in control group were treated with 0.9% NaCl(2 mL•kg-1•d-1)administered through peritoneal injection. After four-week experiment, the pressure was measured in rats througth carotid artery,then the rats were sacrificed , and LVMI,CVF,PVCA and serum NO level were measured. Results In SHR group, SBP,LVMI,CVF and PVCA were higher, serum NO level was decreased obviously than those in control group (P<0.05). After treatment of pancreatic kininogenase,the serum NO level raised obviously,other indexes obviously reduced than those in SHR group (P<0.05),but except SBP,there were no significant difference compared with captopril group (P>0.05). Conclusion Pancreatic kininogenase can obviously reduce the blood pressure and reverse myocardial fibrosis,its mechanism may be concerned with the increasing of NO level in SHR.

Key words: therapeutical use, nitric oxide, endomyocardial fibrosis, rats, inbred SHR

中图分类号: 

  • R544.1